RLMD vs SYK · $692.3M cap vs P/E 35, rev $6.59B
Relmada Therapeutics Inc (RLMD) versus Stryker Corporation (SYK) — a side-by-side from cached financials, not a winner call.
Relmada Therapeutics Inc (RLMD) is a biotechnology company listed on NASDAQ.
Stryker Corporation (SYK) is a medical devices company listed on NYSE.
RLMD does not have a complete income-statement cache yet.
Latest reported SYK revenue for 2026-06-30 was $6.59B. Net income was $1.28B. Revenue was up 9.5% from 2026-03-31 to 2026-06-30. SYK currently screens at market cap $115.45B and trailing P/E 34.9.
RLMD currently screens at market cap $692.3M. SYK currently screens at market cap $115.45B and trailing P/E 34.9.
Not investment advice. Open the RLMD and SYK stock pages for the full models.
Not investment advice.